Merck halts late-stage trial of promising Alzheimera s drug

Drug company Merck said Tuesday it’s halting the late-stage trial of its promising Alzheimer’s drug verubecestat, after an independent study found that it had “virtually no chance” of working. It comes just three months after Eli Lilly announced that it was ending the clinical trial of its Alzheimer’s drug solanezumab, after patients taking it demonstrated no signs of improvement compared to those taking a placebo.

Caring for Elders: Tips for Managing Pain

… to their doctors. “Untreated chronic pain puts a great deal of stress on the body and on the individual’s emotional health as well,” she says. “It can lead to depression, anxiety, reduced mobility and strength, and loss of appetite and sleep.” …

Ostomy Drainage Bags Market Expected to Reach $3,524 Million by 2022, …

According to a new report published by Allied Market Research, titled, “Ostomy Drainage Bags Market: Global Opportunity Analysis and Industry Forecast, 2014-2022,” the ostomy drainage bags market was valued at $2,742 million in 2015, and is expected to reach $3,524 million by 2022, growing at a CAGR of 3.6% from 2016 to 2022. High prevalence of colorectal cancer owing to the increase in geriatric population drives the market growth.